134 related articles for article (PubMed ID: 31839880)
61. Mucosal Proliferations in Completely Examined Fallopian Tubes Accompanying Ovarian Low-grade Serous Tumors: Neoplastic Precursor Lesions or Normal Variants of Benign Mucosa?
Wolsky RJ; Price MA; Zaloudek CJ; Rabban JT
Int J Gynecol Pathol; 2018 May; 37(3):262-274. PubMed ID: 28700429
[TBL] [Abstract][Full Text] [Related]
62. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
63. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
[TBL] [Abstract][Full Text] [Related]
64. KRAS/BRAF Analysis in Ovarian Low-Grade Serous Carcinoma Having Synchronous All Pathological Precursor Regions.
Nakamura K; Nakayama K; Ishibashi T; Ishikawa N; Ishikawa M; Katagiri H; Minamoto T; Sato E; Sanuki K; Yamashita H; Iida K; Sultana R; Kyo S
Int J Mol Sci; 2016 Apr; 17(5):. PubMed ID: 27128903
[TBL] [Abstract][Full Text] [Related]
65. Progressive loss of selenium-binding protein 1 expression correlates with increasing epithelial proliferation and papillary complexity in ovarian serous borderline tumor and low-grade serous carcinoma.
Zhang C; Wang YE; Zhang P; Liu F; Sung CJ; Steinhoff MM; Quddus MR; Lawrence WD
Hum Pathol; 2010 Feb; 41(2):255-61. PubMed ID: 19896693
[TBL] [Abstract][Full Text] [Related]
66. Prognostic indicators in ovarian serous borderline tumours.
Malpica A; Longacre TA
Pathology; 2018 Feb; 50(2):205-213. PubMed ID: 29289348
[TBL] [Abstract][Full Text] [Related]
67. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
[TBL] [Abstract][Full Text] [Related]
68. Benign and Low Grade Serous Epithelial Tumors: Recent Developments and Diagnostic Problems.
Longacre TA
Surg Pathol Clin; 2011 Mar; 4(1):331-73. PubMed ID: 26837298
[TBL] [Abstract][Full Text] [Related]
69. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma.
Kurman RJ
Ann Oncol; 2013 Dec; 24 Suppl 10():x16-21. PubMed ID: 24265397
[TBL] [Abstract][Full Text] [Related]
70. Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations.
Pohl G; Ho CL; Kurman RJ; Bristow R; Wang TL; Shih IeM
Cancer Res; 2005 Mar; 65(5):1994-2000. PubMed ID: 15753399
[TBL] [Abstract][Full Text] [Related]
71. Ovarian serous borderline tumors with recurrent or extraovarian lesions: a Japanese, retrospective, multi-institutional, population-based study.
Baba T; Koshiyama M; Kagabu M; Mikami Y; Minamiguchi S; Moritani S; Ishikawa M; Okamoto A; Terao Y; Nakanishi T; Katabuchi H; Tokunaga H; Satoh T; Konishi I; Yaegashi N
Int J Clin Oncol; 2023 Oct; 28(10):1411-1420. PubMed ID: 37526805
[TBL] [Abstract][Full Text] [Related]
72. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up.
Longacre TA; McKenney JK; Tazelaar HD; Kempson RL; Hendrickson MR
Am J Surg Pathol; 2005 Jun; 29(6):707-23. PubMed ID: 15897738
[TBL] [Abstract][Full Text] [Related]
73. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
74. Epithelial ovarian cancer: rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment.
Despierre E; Yesilyurt BT; Lambrechts S; Johnson N; Verheijen R; van der Burg M; Casado A; Rustin G; Berns E; Leunen K; Amant F; Moerman P; Lambrechts D; Vergote I;
Int J Gynecol Cancer; 2014 Mar; 24(3):468-77. PubMed ID: 24557434
[TBL] [Abstract][Full Text] [Related]
75. KRAS mutation testing in borderline ovarian tumors and low-grade ovarian carcinomas with a rapid, fully integrated molecular diagnostic system.
Sadlecki P; Antosik P; Grzanka D; Grabiec M; Walentowicz-Sadlecka M
Tumour Biol; 2017 Oct; 39(10):1010428317733984. PubMed ID: 28992761
[TBL] [Abstract][Full Text] [Related]
76. KRAS-mutated Uterine Endometrioid Carcinoma With Extensive Surface Changes Resulting in Striking Morphologic Mimicry of an Ovarian Serous Borderline Tumor.
Kir G; Olgun ZC; Gunel H; Ozen F; McCluggage WG
Int J Gynecol Pathol; 2020 Nov; 39(6):573-577. PubMed ID: 31855953
[TBL] [Abstract][Full Text] [Related]
77. [Ovarian serous borderline tumor: the prognostic relation to the pathologic features and management].
Zhou XR; Du XG
Zhonghua Fu Chan Ke Za Zhi; 1994 Oct; 29(10):601-3, 637. PubMed ID: 7712874
[TBL] [Abstract][Full Text] [Related]
78. Correction:
Chui MH; Kjaer SK; Frederiksen K; Hannibal CG; Wang TL; Vang R; Shih IM
Oncotarget; 2021 Jun; 12(13):1323-1324. PubMed ID: 34194631
[TBL] [Abstract][Full Text] [Related]
79. Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages.
Li W; Qiu T; Zhi W; Shi S; Zou S; Ling Y; Shan L; Ying J; Lu N
BMC Cancer; 2015 May; 15():340. PubMed ID: 25929517
[TBL] [Abstract][Full Text] [Related]
80. Simultaneous p53 and KRAS mutation in a high-grade serous carcinoma with deceptive appearance of a low-grade carcinoma. A case report.
Marketkar S; Sung CJ; Quddus MR
Gynecol Oncol Rep; 2023 Jun; 47():101197. PubMed ID: 37251787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
